Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. Additionally we are shipping BCAR3 Kits (8) and BCAR3 Proteins (4) and many more products for this protein.
Showing 10 out of 49 products:
Human Monoclonal BCAR3 Primary Antibody for ELISA, WB - ABIN393728
Bailey, Xie, Do, Montpetit, Diaz, Mohan, Keavney, Yusuf, Gerstein, Engert, Anand: Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. in Diabetes Care 2010
Show all 5 references for ABIN393728
Human Polyclonal BCAR3 Primary Antibody for EIA, IF - ABIN1449996
Riggins, Quilliam, Bouton: Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. in The Journal of biological chemistry 2003
Show all 3 references for ABIN1449996
Human Polyclonal BCAR3 Primary Antibody for IP, PLA - ABIN257737
Sun, Cheng, Chen, Lim, Pallen: Protein tyrosine phosphatase α phosphotyrosyl-789 binds BCAR3 to position Cas for activation at integrin-mediated focal adhesions. in Molecular and cellular biology 2012
Mouse (Murine) Polyclonal BCAR3 Primary Antibody for ELISA, WB - ABIN268560
van Agthoven, van Agthoven, Dekker, van der Spek, Vreede, Dorssers: Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. in The EMBO journal 1998
data presented here suggest that Bcar3 could play a role in testis development
many BCAR3-me (show BCAR1 Antibodies)diated signaling events in epithelial and mesenchymal cells are independent of p130 (show AKT1 Antibodies)Cas association
p130Cas (show BCAR1 Antibodies)- and HEF1 (show NEDD9 Antibodies)-associated AND-34 may regulate B cell adhesion and motility through a Cdc42 (show CDC42 Antibodies)-mediated signaling pathway.
study presents a pluridisciplinary approach, including small-angle X-ray scattering, that provides first insights into the structure of the complex formed between BCAR3 and human enhancer of filamentation 1 (HEF1 (show NEDD9 Antibodies))
BCAR3 is an essential interactor and mediator of HEF1 (show NEDD9 Antibodies)-induced migration.
BCAR3 acts as a putative suppressor of breast cancer progression by inhibiting the prometastatic TGFbeta (show TGFB1 Antibodies)/Smad (show SMAD1 Antibodies) signaling pathway in invasive breast tumors.
BCAR1 (show BCAR1 Antibodies) and BCAR3 scaffolding proteins have roles in cell signaling and antiestrogen resistance
Taken together, these results demonstrated that BCAR3 plays an important role in the signaling pathways of insulin (show INS Antibodies) leading to cell cycle progression and cytoskeleton reorganization, but not GLUT4 (show SLC2A4 Antibodies) translocation.
BCAR3 promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells.
BCAR3 expression may regulate Src (show SRC Antibodies) signaling in a BCAR3-p130(cas (show BCAR1 Antibodies)) complex-dependent fashion by altering the ability of the Src (show SRC Antibodies) SH3 domain (show ITSN1 Antibodies) to bind the p130(cas (show BCAR1 Antibodies)) SBD (show TRAPPC4 Antibodies)
BCAR3-p130Cas (show BCAR1 Antibodies) complex formation is not required for BCAR3-mediated anti-estrogen resistance, Rac (show AKT1 Antibodies) activation or discohesion of epithelial breast cancer cells
the c-Src/Cas/BCAR3 signaling axis is a prominent regulator of c-Src activity, which in turn controls cell behaviors that lead to aggressive and invasive breast tumor phenotypes
AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner
BCAR3 and NSP1 (show SH2D3A Antibodies) are more highly expressed than SH2D3C (SHEP1 (show SH2D3C Antibodies)) in breast cancer cells, and the expression patterns suggest differential roles for the three genes during breast cancer progression.
Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. Breast cancer anti-estrogen resistance gene 3 was identified in the search for genes involved in the development of estrogen resistance. The gene encodes a component of intracellular signal transduction that causes estrogen-independent proliferation in human breast cancer cells. The protein contains a putative src homology 2 (SH2) domain, a hall mark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48. Multiple transcript variants encoding different isoforms have been found for this gene.
breast cancer anti-estrogen resistance 3
, breast cancer antiestrogen resistance 3
, breast cancer anti-estrogen resistance protein 3
, breast cancer anti-estrogen resistance protein 3-like
, p130Cas-binding protein AND-34
, SH2 domain-containing protein 3B
, breast cancer antiestrogen resistance 3 protein
, dJ1033H22.2 (breast cancer anti-estrogen resistance 3)
, novel SH2-containing protein 2